Ceapro Inc. (TSX-V: CZO) is a Canadian biotechnology company involved in the development and commercialization of "active ingredients" derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

Ceapro's patented process technologies include Pressurized Gas eXpanded (PGX) technology which is a unique and disruptive technology with several key advantages over conventional drying and purification methods that can be used to generate novel high-value biopolymers and biocomposites structures with micro or nano-sized features. Ceapro also utilizes its proprietary plant extraction-based manufacturing process to supply ingredients to well-known personal care and cosmetic industries worldwide.

The Company's two value-driving products, oat beta glucan and avenanthramides, are found in many household names, cosmetic and personal care brands. These products are manufactured from Ceapro's proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Oat beta glucan effectively stimulates collagen synthesis and deeply moisturizes the skin (epidermis and dermis) thereby improving skin restructuring, decreasing wrinkles and allowing wound healing with minimal scaring. When taken orally, oat beta glucan has been shown to improve cholesterol levels and therefore has "heart health" approved health claims in Canada, United States and Europe. Avenanthramides are polyphenolic compounds found exclusively in oats which act as natural anti-oxidant, anti-irritant and anti-inflammatory. When added to topical formulation, avenanthramides effectively reduce redness and itchiness due to inflammation. In oral formulations, avenanthramides could treat serious conditions triggered by inflammation. Given the therapeutic benefits of the Company's two flagship products, Ceapro is currently expanding and developing them for use in the nutraceutical industries.